XOMA ROYALTY CORPORATION (XOMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.170.00%
Close 2026-07-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
XOMA raised revenue guidance to $225M-$250M for 2026. EPS guidance rose to $8.50-$9.50. The acquisition by Ligand adds value and growth potential. Recent earnings beats show operational strength.
Revenue growth may slow, missing the $225M target. EPS could fall below $8.50. The acquisition might hurt revenue and valuation. Analyst estimates have recently dropped.
The price is about 22% above our fair value near $36. Analysts expect 5% revenue growth. We see risk in meeting high guidance amid recent cuts.
Breaks if: Acquisition not completed by mid-2026
Breaks if: EPS falls below $8.50 in FY26
Breaks if: Revenue falls below $225 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company has shown strong recent financial performance but faces volatility in management and elevated risks in the healthcare sector.
The current valuation reflects a high level of fragility due to expensive pricing, weak execution quality, and a turbulent sector backdrop. The market appears to be pricing in a significant expectations gap, suggesting that investors are cautious about future performance.
Management has made progress in raising revenue and earnings guidance, but the actual results have not yet fully met these targets. The near-term risk of missing expectations remains relatively low, but the company operates in a high-miss-rate industry.
The thesis hinges on management's ability to execute on their growth plans and the overall performance of the healthcare sector. Key scenarios include potential credibility issues if guidance is cut and the impact of broader economic conditions on the company's performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, XOMA's performance will depend on management execution and sector dynamics. Not investment advice.